Day One Biopharmaceuticals, Inc.
DAWN
$7.46
$0.497.03%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 313.92% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 313.92% | -- | -- | -- | -- |
| Cost of Revenue | 432.53% | -- | -- | -- | -- |
| Gross Profit | 302.71% | -- | -- | -- | -- |
| SG&A Expenses | -4.03% | 10.42% | 34.13% | 58.53% | 76.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.00% | 16.29% | 58.85% | 24.66% | 149.72% |
| Operating Income | 69.54% | 33.51% | -9.77% | 157.61% | -133.09% |
| Income Before Tax | -962.07% | 42.33% | -8.68% | 178.34% | 93.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -588.04% | 42.33% | -20.55% | 180.25% | 90.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -588.04% | 42.33% | -20.55% | 180.25% | 90.39% |
| EBIT | 69.54% | 33.51% | -9.77% | 157.61% | -133.09% |
| EBITDA | 70.23% | 34.81% | -8.75% | 158.80% | -132.48% |
| EPS Basic | -481.42% | 51.32% | -1.26% | 171.39% | 91.73% |
| Normalized Basic EPS | -797.07% | 47.10% | 8.71% | 169.70% | 94.64% |
| EPS Diluted | -481.42% | 51.32% | -0.96% | 170.37% | 91.73% |
| Normalized Diluted EPS | -797.07% | 47.10% | 8.71% | 169.46% | 94.64% |
| Average Basic Shares Outstanding | 18.31% | 18.49% | 19.06% | 12.41% | 16.22% |
| Average Diluted Shares Outstanding | 18.31% | 18.49% | 19.06% | 12.78% | 16.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |